Abstract
We introduce a label-free surface-enhanced Raman scattering (SERS) biosensing platform equipped with metallic nanostructures that can identify the efficacy of Oxford-AstraZeneca (AZD1222) vaccine in vaccinated individuals using non-invasive tear samples. We confirmed the hypothesis that the tears of people who receive the AZD1222 vaccine may be similar to those of adenovirus epidemic keratoconjunctivitis patients since the Oxford-AstraZeneca vaccine is derived from a replication-deficient ChAdOx1 vector of chimpanzee adenovirus. Additionally, we confirmed the potential of the three markers for estimating the vaccination status via analyzing the signals emanating from antibodies or immunoglobulin G by-product using our label-free, SERS biosensing technique with a high reproducibility (<3% relative standard deviation), femtomole-scale limit of detection (1 × 10 -14 M), and high SERS response of >10 8 . Therefore, our label-free SERS biosensing nanoplatforms with long-term storage and robust stability will enable rapid and robust monitoring of the vaccine presence in vaccinated individuals.
Keywords: Label-free SERS biosensing platform; Near- and far-field properties; Oxford-AstraZeneca vaccine; Stability and robustness; Tear fluids.
【저자키워드】 Label-free SERS biosensing platform, Near- and far-field properties, Oxford-AstraZeneca vaccine, Stability and robustness, Tear fluids., 【초록키워드】 Efficacy, Vaccine, vaccination, antibody, Adenovirus, AZD1222, Immunoglobulin G, Epidemic, stability, Immunoglobulin, Patient, limit of detection, ChAdOx1, platform, marker, Hypothesis, Oxford-AstraZeneca, Vaccination Status, Standard deviation, Non-invasive, lAbel, product, vaccinated individuals, reproducibility, robustness, vaccinated individual, fluids, tears, Keratoconjunctivitis, Tear, robust, Epidemic keratoconjunctivitis, identify, the vaccine, receive, scattering, 【제목키워드】 Efficacy, COVID-19 vaccination, AstraZeneca, vaccinated individual,